PUBLISHER: Grand View Research | PRODUCT CODE: 1405811
PUBLISHER: Grand View Research | PRODUCT CODE: 1405811
The global pulmonary stents market size is expected to reach USD 306.09 million by 2030, registering a CAGR of 4.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and lung cancer, is a major driving force behind the expansion of the market. According to the Global Initiative for Asthma (GINA), about 200 million people worldwide are affected by COPD, with an estimated 3.2 million deaths annually. Lung cancer, a leading public health concern in the U.S., is witnessing a rise in incidence and mortality rates, further fueling the growth of the market. These stents are employed to treat various respiratory conditions, including lung cancer.
According to projections from the American Cancer Society, it is anticipated that approximately 238,340 new cases of lung cancer were diagnosed in the United States in 2023. Most of these diagnoses are expected to be in individuals aged 65 and above, with a relatively small percentage affecting those under 45. This disease poses a significant public health threat, particularly among older adults, with an average age of diagnosis around 70 years. Notably, lung cancer ranks as the leading cause of cancer-related deaths in the U.S., contributing to one in every five cancer fatalities. Annually, more lives are lost to lung cancer than the combined total of deaths from breast, colon, and prostate cancer.
The pulmonary stents industry is experiencing notable growth due to advancements in new stent technologies, particularly in the areas of 3D-printed self-expanding stents (3DPSS), biodegradable stents (BS), and drug-eluting stents (DES). According to a study published in November 2023 by the National Center for Biotechnology Information (NCBI), these innovations offer several advantages over traditional stents, including improved patient outcomes, reduced complication rates, and enhanced quality of life.